Most adults with MRI-confirmed cartilage damage are eligible

For most adults researching cartilage damage, the first question is a practical one: could the ChondroFiller injection actually work for me? The short answer, for the majority of patients, is that the eligibility bar is deliberately broad.

The ChondroFiller injection is suitable for any adult with cartilage wear visible on MRI, whether that wear is a contained focal defect or more diffuse loss spread across the joint surface. Crucially, neither age nor the size of the defect acts as a hard barrier — which sets this pathway apart from surgical cartilage-regeneration options that typically require a contained lesion and a younger patient's regenerative biology.

Strong positive indicators include post-traumatic chondral lesions, osteochondritis dissecans (OCD), and cartilage loss that has developed after a meniscal injury or ligament reconstruction. Patients with early-to-advanced osteoarthritis are also assessed, and active patients in their 60s, 70s, and beyond are explicitly included — the injection pathway is used as a pre-replacement option for those wanting to defer or avoid joint surgery.

The procedure itself is ultrasound-guided and carried out on an outpatient basis, without the anaesthetic and recovery demands of a theatre-based operation. The scaffold works by supporting matrix-induced chondrogenesis: it provides a structural framework that recruits the patient's own progenitor cells to support the body's own repair processes.

The sections that follow set out what imaging, joint mechanics, and clinical assessment determine before a treatment plan is confirmed.

What your MRI scan needs to show

Cartilage carries no nerve supply, which means structural damage can be well advanced before symptoms become disabling. That gap between what a patient feels and what is actually happening inside the joint is precisely why imaging — not symptom score or X-ray appearance alone — drives the eligibility decision at the London Cartilage Clinic.

An MRI scan is the clinical entry point. The scan can reveal a contained focal chondral defect, diffuse articular surface loss across one or more compartments, or an osteochondral lesion (OCD) where damage extends into the subchondral bone. All three presentations fall within the scope of the ChondroFiller injection pathway, provided the joint is mechanically stable — a condition covered in the following section.

Advanced imaging findings, including a 'bone on bone' appearance, do not trigger automatic exclusion. The treating clinician evaluates such cases through a structured four-lens framework: physics (how the joint is loaded and aligned), chemistry (the inflammatory environment within the joint), biology (the patient's regenerative capacity at that stage of life), and timing (where the patient sits in the natural history of their condition). Together, these lenses determine whether the injection pathway remains appropriate or whether a different approach better fits the clinical picture.

The scan also guides which of the clinic's four clinical pathways — Prevention, Regeneration, Combination, or Support — best matches the patient's presentation.

Which joints can receive the ChondroFiller injection

Eight joints are eligible for the ChondroFiller injection: knee, hip, shoulder, ankle, elbow, wrist, thumb and small hand joints, and the temporomandibular joint (TMJ). Across all of them, ultrasound guidance makes precise image-guided placement feasible — including at anatomically complex sites where unguided injection would carry unnecessary risk.

The evidence base is deepest for the knee. Two controlled studies — Schneider et al. (2016) and Simeonov et al. (2024) — documented significant IKDC and Lysholm score improvements at 12 months in patients with both traumatic and degenerative presentations. Hip applicability is supported by a 2025 case report in which a 32-year-old with a 15 mm × 5 mm chondral lesion of the femoral head achieved complete pain relief and full range of motion after ChondroFiller application, without microfracture. For smaller joints, a 2025 wrist series (n=59 intra-articular distal radius fractures) showed significantly better cartilage quality at follow-up arthroscopy when ChondroFiller was used for defects of 0.5–2 mm — with only 0.2–0.3 mL of the 1 mL preparation needed per defect, confirming that scaffold volume can be calibrated to sub-millimetre precision.

It is worth being honest about what the evidence covers: the knee has the strongest trial data, while hip and wrist support comes from case-level series rather than controlled trials. That distinction matters when weighing individual expectations, and a clinical consultation will clarify what the current evidence supports for a specific joint and presentation.

Where a single joint has multiple compartments affected, the number of ChondroFiller boxes — one, two, or three — is adjusted at consultation to match the extent of involvement, rather than defaulting to a surgical alternative.

When something needs correcting before the injection

The ChondroFiller scaffold needs one thing above all else to integrate properly: a joint that loads and moves within acceptable mechanical limits. A 2024 biomechanical in-vitro study confirmed that early scaffold instability can compromise tissue response under cyclic loading — which is why untreated ligament laxity, significant axial malalignment, or a meniscal deficit actively driving ongoing cartilage loss must be addressed before the injection, or concurrently with it. The collagen matrix cannot bed in reliably if the joint continues to shift or bear load abnormally during the early integration window.

Addressing these factors does not close the door on the ChondroFiller injection. For most patients, correction is a preparatory step rather than a disqualifier. Once joint mechanics are restored — whether through ligament reconstruction, realignment, or meniscal repair — the injection pathway remains available.

A small number of additional factors should be raised at consultation: active joint infection, inflammatory or immune-mediated arthritis affecting the joint, and known allergy to collagen are each reasons to pause before proceeding. These are not automatic barriers, but they need direct clinical review to determine how or whether to continue.

The clinic's eight-step self-assessment on the suitability page is designed to help patients identify any of these considerations ahead of booking, so that the consultation itself can focus on treatment planning rather than preliminary screening.

How the clinic assessment and dose plan work

Before the appointment begins, the London Cartilage Clinic offers a structured eight-step self-assessment on its suitability page — patients work through their imaging findings, joint history, and mechanical status so the consultation can move directly to treatment planning rather than preliminary screening.

At that consultation, Professor Paul Lee uses a four-lens framework to assess joint readiness: physics (mechanical loading and alignment), chemistry (the tissue environment), biology (the patient's own regenerative capacity), and timing (how long the damage has been present and how it is progressing). Together, the four lenses determine whether the scaffold is appropriate and, if so, which of the clinic's four pathways — Prevention, Regeneration, Combination, or Support — fits the presentation.

MRI review at consultation settles the dose plan. Scan findings determine the appropriate number of scaffold boxes, calibrated to the extent and distribution of the damage, so this decision is fixed before the injection day rather than revisited on arrival.

The injection itself is an outpatient procedure, carried out under ultrasound guidance at the London Cartilage Clinic on Harley Street. No general anaesthetic is required. Technique precision matters at this stage: placing the scaffold flush with the articular surface — rather than overfilling the defect — directly affects integration quality, as confirmed by the 2025 wrist series, in which overfilling produced fibrous rather than hyaline-like tissue.

A period of restricted weight-bearing follows the injection. Allowing the scaffold time to stabilise within the joint environment before full loading resumes is a standard part of the clinical protocol, and the point at which that restriction lifts is reviewed at the six-week follow-up included in the pathway.

What the clinical evidence shows — and where gaps remain

The knee outcomes are the most thoroughly documented. In the 2016 multicentre RCT, IKDC scores — a validated composite of knee pain, function, and activity level — improved by roughly 30 points over 12 months versus baseline, with MRI confirming scaffold integration from week four and no adverse events recorded. A 2024 single-centre Bulgarian cohort (n=17, mean age 31) replicated those gains across both traumatic and degenerative lesions, with Lysholm and IKDC scores plateauing between months six and twelve, suggesting a stable rather than a temporary effect.

For patients with more advanced disease, a 2025 prospective Vienna trial (n=25, Kellgren-Lawrence Grade IV OA) found that adding ChondroFiller® intra-articularly to an autologous MSC concentrate produced superior KOOS scores — a quality-of-life index covering pain, stiffness, and daily function — compared with MSC therapy alone. A meaningful between-group difference at two months supports the clinic's position that advanced disease is not a hard ceiling when an appropriate co-delivery strategy is used.

Published case and cohort data confirming multi-joint applicability have already been covered above; they reinforce the pattern rather than contradict it.

Most trials to date are small and follow-up rarely exceeds 12 months — that is the honest summary of where the evidence sits. For a patient weighing the ChondroFiller injection against other options, the data provide a reasonable foundation, not a guarantee. The practical question at assessment is whether your specific joint, damage pattern, and biology match the profiles in which clinical gains have been demonstrated — a question that cannot be answered from published averages alone.

That assessment is available at the London Cartilage Clinic on Harley Street — book via londoncartilage.com.

1. [1] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
2. [2] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
3. [3] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Implantation of ChondroFiller Liquid® as a scaffold material forthe treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
6. [6] Joint Preservation in Patients with Grade IV Osteoarthritis of the Knee: Use of an Acellular Collagen Scaffold (ChondroFiller® Liquid) and Blood Derived Stem Cell Rich Graft. (2025). https://doi.org/10.29011/2575-9760.011360 https://doi.org/10.29011/2575-9760.011360